The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

DNA damaging agents such as radiotherapy and gemcitabine are frequently used for the treatment of pancreatic cancer. However, these treatments typically provide only modest benefit. Improving the low survival rate for pancreatic cancer patients therefore remains a major challenge in oncology. Inhibi...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer biology & therapy Vol. 13; no. 11; pp. 1072 - 1081
Main Authors:	Prevo, Remko, Fokas, Emmanouil, Reaper, Philip M., Charlton, Peter A., Pollard, John R., McKenna, W. Gillies, Muschel, Ruth J., Brunner, Thomas B.
Format:	Journal Article
Language:	English
Published:	United States Taylor & Francis 01.09.2012 Landes Bioscience
Subjects:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Ataxia Telangiectasia Mutated Proteins ATR Binding Biology Bioscience Calcium Cancer Cell Cell Cycle Checkpoints - drug effects Cell Cycle Checkpoints - radiation effects Cell Cycle Proteins - antagonists & inhibitors Cell Hypoxia - physiology Cell Line, Tumor chemotherapy Combined Modality Therapy Cycle Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - pharmacology DNA Damage DNA Repair Gemcitabine Humans hypoxia inhibitor Landes Organogenesis Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - enzymology Pancreatic Neoplasms - pathology Pancreatic Neoplasms - radiotherapy Phosphorylation Protein Serine-Threonine Kinases - antagonists & inhibitors Proteins Pyrazines - administration & dosage Pyrazines - pharmacology Radiation-Sensitizing Agents - pharmacology radiosensitivity Research Paper Signal Transduction Sulfones - administration & dosage Sulfones - pharmacology
ISSN:	1538-4047, 1555-8576, 1555-8576
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!